semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 1.0-70.0,  Sickle Cell Disease Hemoglobinopathies Patients who are ineligible for BMT from an HLA-matched sibling donor can proceed to a haplo-BMT. Patients with an HLA-matched related donor will proceed to a matched BMT Age 1-70 years Good performance status (ECOG 0 or 1; Karnofsky and Lansky 70-100) Patients and donors must be able to sign consent forms. First degree relative should be willing to donate Patients must be geographically accessible and willing to participate in all stages of treatment Eligible diagnoses: Patients with sickle cell anemia such as sickle cell anemia (Hb SS), Hb Sβ° thalassemia, Hb Sβ+thalassemia, Hb SC disease, Hb SE disease, Hb SD disease, Hemoglobin SO Arab disease HbS with hereditary persistence of fetal hemoglobin. Other significant hemoglobinopathies. Plus one of the following Attenuation of progressive disease (adults) Severe and debilitating vaso-occlusive pain despite hydroxyurea or regular blood transfusion therapy Stroke and silent infarct; stroke or central nervous system event lasting more than 24 hours; MRI changes indicative of brain parenchyma damage and MRA evidence of cerebrovascular disease  Poor performance status (ECOG>1) Poor cardiac function: left ventricular ejection fraction<35% Poor pulmonary function: FEV1 and FVC<40% predicted Pulmonary hypertension moderate to severe by echocardiographic standards Poor liver function: direct bilirubin >3.1 mg/dl HIV-positive Minor (donor anti-recipient) ABO incompatibility if an ABO compatible donor is available Prior transfusions from donor or recipient if caused alloimmunization vs. donor cells Women of childbearing potential who currently are pregnant (Beta-HCG+) or who are not practicing adequate contraception Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow-up. However, patients with history of stroke and significant cognitive deficit,that would preclude giving informed consent or assent will not be excluded, if they have a family member or significant other with Power of Attorney to also consent of their behalf. FOR DONOR
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 6.0-20.0,  Sickle Cell Disease Asthma Patients are aged 6 years old up to 21 years old Children with sickle cell disease with the genotype SS, SC, or S β 0 thal African American children with asthma who do not have sickle cell disease or sickle cell disease trait African American children with no chronic disease Physician diagnosed asthma and atopy (of any asthma severity) plus a family history of asthma 89,90 Patients whose controller respiratory medications and maintenance medications for sickle cell disease (e.g. hydroxyurea) have been unchanged for the previous 4 weeks  Patients who are current smokers Patients who had an inflammatory event related to sickle cell disease (pain episode, priapism, acute chest syndrome, urgent medical visit), asthma exacerbation, or respiratory infection within 1 month prior to the blood, saliva, and urine collection Patients who are receiving chronic transfusion therapy and who have received a transfusion within 90 days prior to blood, saliva, and urine collection Patients who have received treatment with a leukotriene synthesis inhibitor or a leukotriene modifier[montelukast (Singulair®)] within the 2 weeks prior to blood and urine collection Women who are pregnant or lactating
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Patients With Severe Chronic Pain Patient is at least 18 years of age at the time of study entry Patient who has severe chronic pain, whom IT therapy is warranted, and who is intolerant of, or refractory to other treatments, such as systemic analgesics, adjunctive therapies, and/or IT morphine Patient is planned to be initiated on IT as the sole agent in the pump at a participated site Patient has not received treatment administered continuously via Medtronic SynchroMed® II pump within the past 30 days Patient has a life expectancy >6 months as determined by the physician Patient is able to read, understand, and voluntarily sign the IRB-approved informed consent document prior to the performance of any study-specific procedures Patient is able to understand and complete required assessments  Patient has a known hypersensitivity to or any of its formulation components Patient has a pre-existing history of psychosis Patient has infection at the microinjection site, uncontrolled bleeding diathesis, or known spinal canal obstruction that impairs circulation of cerebrospinal fluid Patient is being initiated with in conjunction with other IT agents Patients with any other concomitant treatment or medical condition that, in the opinion of the clinician, would render IT administration hazardous
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 16.0-65.0,  Sickle Cell Disease Key Sickle Cell Disease (HbSS, HbSC, HbSβ⁰-thalassemia, or HbSβ⁺-thalassemia) If receiving hydroxyurea or erythropoietin, treatment must have been prescribed for at least 6 months, with the dose stable for at least 3 months Between 2 and 10 sickle cell-related pain crises in the past 12 months Key  On a chronic transfusion program or planning on exchange transfusion during the study Hemoglobin <4.0 g/dL Planned initiation, termination, or dose alteration of hydroxyurea during the study Receiving chronic anticoagulation therapy (e.g. warfarin, heparin) other than aspirin
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 0.75-4.0,  Iron Deficiency Anemia Age ≥ 9 to < 48 months 2. IDA documented by hematologic indices (hemoglobin, MCV, RDW, reticulocyte count, reticulocyte hemoglobin content), serum ferritin, serum iron and total iron binding capacity  Iron deficiency likely or definitely due to blood loss from the intestine or other sites. 2. Evidence of response to recent/current oral iron therapy, as determined by increase in hemoglobin by > 1.0 gm/dL and MCV by 5 fL above measurements prior to iron therapy 3. History or evidence of intestinal malabsorption 4. History of prior intravenous iron therapy 5. Major co-morbidity such as a serious chronic medical condition unrelated to iron deficiency apparent on history, physical examination, or laboratory tests 6. Other causes of anemia (sickle cell disease, thalassemia, other hemolytic anemia, bone marrow failure, etc.) apparent by history, physical examination, and/or laboratory tests. 7. High likelihood of suboptimal adherence by parents with study requirements (previous missed clinic visits) 8. Inability to tolerate oral medications 9. History of birth at < 30 weeks gestation 10. Other medical or social factors at discretion of treating physician
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Family Study HbA2 Leuven Mutation. Family history of HbA2 Leuven mutation  Any condition inhibiting simple blood withdrawal
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Low Trauma Non Vertebral Fracture Patients of more than 50 years old Low trauma non vertebral fracture Ambulatory patient Direct access to mobile phone (or access with the help of a close person) and ability to communicate via SMS Patient who doesn't oppose to his participation in the study Affiliation to the social security  Patients hospitalized for the fracture in the orthopaedics department because these more severe patients have a systematic screening and management of osteoporosis Fractures whose location is not suggestive of osteoporotic fracture (cervical spine, skull, hands, fingers, toes) Pathological fractures (cancer or myeloma) Traumatic fractures Severe alterations of cognitive functions Resident subjects except Paris and the surrounding area
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 16.0-999.0,  Anemia, Sickle Cell Sickle Cell Anemia Sickle Cell Disease Sickle Cell Disorders Hemoglobin SC Disease Sickle Cell Hemoglobin C Disease Signed Informed Consent (and assent as required for minors) Diagnosis of SCD (known HbSS or HbSß0) Sixteen years of age or older Prior history of at least one VOC requiring hospitalization within the last 24 months  ≥ 5 VOCs within the preceding 6 months requiring Emergency Room (ER) visits or hospital admissions History of overt stroke or cerebral vascular accident within the previous 12 months Remained in the hospital for ≥2 weeks (14 days) for VOC management within the previous 6 months Known pulmonary hypertension based on an estimated tricuspid regurgitant jet velocity (TRJV) >2.90 m/s or definitive diagnosis by prior right heart catheterization Baseline SaO2 level by pulse oximetry <92% on room air Systemic hypertension (baseline systolic pressure ≥ 160 mmHg or diastolic pressure ≥ 90 mmHg) History of myocardial infarction, myocardial ischemia, or angina On a chronic red blood cell transfusion therapy program (simple or exchange) Renal dysfunction presenting with a GFR<60 mL/min/1.73m Any diagnosis of a concurrent chronic debilitating disease that may affect the completion of the study or results of the study as determined by the investigator
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 5.0-25.0,  Sickle Cell Disease Hb-SS Disease With Vasoocclusive Pain Hemoglobin SS Disease With Vasoocclusive Crisis Other Sickle Cell Disease With Vaso-Occlusive Pain Hemoglobin SS Disease With Crisis Diagnosis of sickle cell disease (Hb SS, HbSC, HbS-β0-thalassemia) 2. Age 5.00 to 24.99 years 3. Pain consistent with vaso-occlusive crisis that meets the for hospitalization and parenteral narcotics: moderate-severe pain unresponsive to oral medications (NSAIDS + narcotics) that has no alternative etiology (e.g., trauma) 4. Platelet count >100,000 5. INR <1.2, PTT < 40 seconds 6. Negative urine pregnancy test for females of child-bearing potential, including any female ≥10 years of age 7. Informed consent by patient (≥18 years of age) or parent (if patient <18 years of age); assent from patients 12-18 years of age 8. Ability to start drug/placebo infusion within 16 hours of admission  History of stroke (either ischemic or hemorrhagic) 2. Currently receiving anticoagulation medication (heparin within 1 week, Coumadin within 3 weeks) or medication with irreversible anti-platelet effect (e.g., aspirin, ticlopidine) within 14 days 3. Red cell transfusion within 60 days 4. Major surgery within 30 days 5. Treatment with hydroxyurea within 30 days (due to evidence that hydroxyurea can reverse platelet activation in patients with SCD) 6. Tmax ≥ 102.0o F without concomitant signs of infection, or ≥ 100.4o F with any finding suggestive of bacterial infection, including acute chest syndrome (fever, respiratory symptoms, and new infiltrate on chest X-ray) 7. Active internal bleeding 8. Known allergy to abciximab or murine proteins 9. Recent (within 6 weeks) gastrointestinal or genitourinary bleeding of clinical significance 10. Bleeding diathesis 11. History of vasculitis 12. Intracranial neoplasm, arteriovenous malformation or aneurysm 13. Severe uncontrolled hypertension 14. Patients who previously participated in the study must be excluded due to the increased risk of severe thrombocytopenia
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  The Focus of the Study is the Quality and Amount of Regenerated Articular Cartilage. Participant is willing and able to give informed consent for participation in the study Male or Female, aged 18 years to 65 years Diagnosed with articular cartilage defect in the knee (ICRS/Outerbridge grade III/IV cartilage lesions as assessed on MRI scan) No other significant medical co-morbidities, as assessed by pre-operatively, that could interfere with surgery results of trial eg. Hypertension, COPD etc Participant has clinically acceptable laboratory and ECG tests at pre-assessment clinic Able (in the Investigators opinion) and willing to comply with all study requirements Up to 3 lesions of sizes 2-8 cm2  Generalized and/or inflammatory arthritis Active joint inflammation More than 5 degrees of varus or valgus deformity Age below 18 and over 65 years More than 4 lesions Lesions more than 8 cm2 Significant co-morbidities or classified as ASA grade 3/4
Patient description: The patient is a 34-year-old African American man with the known history of Sickle cell disease comes to the clinic with severe bone pain. The patient had severe pain in his lower back that radiated to both thighs scored 9 out of 10. The patient has had positive history of sickle cell crises since childhood. He also had the same symptoms in past two weeks treated with oxycodone which was not beneficial to his pain. His PCP sent him to the emergency department to receive intra venous pain modulators. The patient is afebrile within the normal blood pressure. No splenomegaly was detected in the physical exam. He has no positive history of drug allergy. He won't smoke or uses any illicit drugs. The lab study is as bellow: Hgb: 8 g/dl WBC: 10000 /mm3 Plt: 300000 /ml MCV: 106 fL Hemoglobine electrophoresis: 91% HbS 6%HbF 3%HbA2 AST: 22 U/L ALT: 43 U/L Alk P: 53 U/L Ferritin: 1200 ng/ml

Clinical trial eligibility criteria: eligible ages (years): 1.0-3.917,  Sickle Cell Anemia Sickle Cell Disease Malaria Pediatric subjects with documented sickle cell anemia (HbSS supported by hemoglobin electrophoresis or by peripheral blood smear showing sickled red blood cells) Age range of 1.00-3.99 years, inclusive, at the time of enrollment Weight at least 5.0 kg at the time of enrollment Willingness to comply with all study-related treatments, evaluations, and follow up  Known chronic medical condition (e.g., HIV, malignancy, active clinical tuberculosis) Severe malnutrition determined by impaired growth parameters as defined by WHO (weight for length/height or weight-for-length/height > 3 z-scores below the median WHO growth standards) Pre-existing severe hematological toxicity: 1. Hb <4.0 g/dL 2. Hb <6.0 g/dL AND ARC <100 x 10E9/L 3. Hb <7.0 g/dL AND ARC <80 x 10E9/L 4. Platelets <80 x 10E9/L 5. ANC <1.0 x 10E9/L Alanine transaminase (ALT) or creatinine >2 times the upper limit of normal for age Blood transfusion within 30 days prior to enrollment